DOCSLIB.ORG

Augmentation of 6-Aminonicotinamide Antagonism of Tumor Growth by Compounds with Estrogenic0 Activity*

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Augmentation of 6-Aminonicotinamide Antagonism of Tumor Growth by Compounds with Estrogenic0 Activity* Augmentation of 6-Aminonicotinamide Antagonism of Tumor Growth by Compounds with Estrogenic0 Activity* L. S. DIETRICH (Department of Biochemistry, University of Miami, School of Medicine, Miami, Florida) SUMMARY The hormonal derivatives diethylstilbestrol, hexestrol, dienestrol, cortisone, estra- diol-17a, estradiol-17/3, progesterone, and phloretin were compared with regard to their capacity to enhance carcinostasis in the presence of the niacin antagonist 6- aminonicotinamide. Diethylstilbestrol and hexestrol were found to be more powerful than either estradiol-17/îor dienestrol. Phloretin, estradiol-17a, and progesterone were without activity. Cortisone, either alone or in the presence of 6-aminonicotinamide, exhibited slight antitumor activity. In the absence of 6-aminonicotinamide, diethylstilbestrol, hexestrol, dienestrol, and estradiol-17/3 had no antitumor activity. The suggestive correlation between estrogenic activity and enhancement of carcino stasis in the presence of 6-aminonicotinamide is discussed. Adenocarcinoma 755 grown in C57BL mice is sensitive materials dissolved in sesame oil were administered intra- to the niacin antagonist 6-aminonicotinamide (5). More peritoneally and intramuscularly, respectively. Adminis recently it has been shown that combined therapy of tration of the hormonal agents and vitamin antagonist diethylstilbestrol and 6-aminonicotinamide has greater was carried out on well established tumors (14-20 days antitumor effect than either drug by itself (3). When the old) and continued for 6 consecutive days. In order to activities of various cytochrome-linked pyridine nucleo- tide-dependent enzymes of tumors from animals treated TABLE 1 with these drugs were measured (1), it was shown that, EFFECTOF ESTROGENSONTHE GROWTHOFTHE although diethylstilbestrol had no effect on the activity ADENOCAHCINOMA755 of these enzymes, combined therapy with the hormone and cent 6-aminonicotinamide markedly increased the enzymatic Group*Sesame tumor wt, weight inhibition observed by the administration of 6-amino S.E.)t1.92(gm.± change+3+4-2+ nicotinamide (6-AN). The hyperphysiological levels of the estrogens employed oilEstradiol-170HexestrolDienestrolSesame0.322.39± in these studies raised the question as to whether the tumor 0.302.84± 0.391.74± growth inhibition observed was owing to the estrogenic 0.311.75± 1+12+5+30+ properties of the drug or to functional groups of the mole cule unrelated to hormonal action. An elucidation of this oilStilbestrolSaline 0.201.32± question motivated the studies to be reported. 0.174.53± MATERIALS AND METHODS controlCortisone 0.432.43± C57BL mice, 2-4 months old, weighing 18-22 gm., were acetateAverage ±0.32ÃŽMortality0/200/200/200/200/140/150/200/20Per15 housed in plastic cages in an air-conditioned, constant- * Hormones were dissolved in sesame oil, with the exception temperature room (74°F.). All mice received, ad libitum, of cortisone acetate, which was suspended in saline. All hor a diet of Rockland pellets and water. The neoplasm em mones were given at a level of 10 mg/kg for 6 consecutive days. ployed was the mammary Adenocarcinoma 755, trans t S.E. = standard error = planted into the axillary region by the usual trocar technic. n- 1) 6-Aminonicotinamide, dissolved in saline, and estrogenic ÃŽ"t" value of this experiment was 2.7. * This work was supported in part by Grant CY-4868 and a The results of two additional experiments with each of the Career Development Award GM-K3-15,186 from the United States estrogens were similar to the tabulated examples. In three Public Health Service. other experiments with cortisone acetate no inhibition was Received for publication July 5, 1963. obtained. 61 Downloaded from cancerres.aacrjournals.org on September 25, 2021. © 1964 American Association for Cancer Research. 02 Cancer Research Vol. 24, January 1964 note any delayed host toxicity, a waiting period of 5-6 The effect of combining 6-aminonicotinamide and vari days of no treatment was observed after the last injection. ous estrogenic and nonestrogenic substances is presented At the end of this period the animals were sacrificed, the in Tables 2 and 3. Diethylstilbestrol, at a level of 1 mg/ tumors removed, and wet weights were determined to the kg, had no effect on tumor growth when given along with nearest 10 mg. the niacin antagonist 6-aminonicotinamide. Increasing the level of estrogen to 4 mg/kg resulted in a significant RESULTS suppression of tumor growth as compared with 6-AN The effect of the various hormone derivatives on the alone. Raising the level of hormone administered to 10 growth of the 755 tumor is presented in Table 1. The mg/kg produced no greater tumor toxicity but seemed to compounds hexestrol, diethylstilbestrol, dienestrol, and increase host toxicity. In the case of hexestrol and estradiol-17/3, when administered at a level of 10 mg/kg, dienestrol neither compound exhibited activity when ad did not inhibit the growth of the 755 tumor and exhibited ministered at 1 mg/kg. Raising the level of hexestrol to little host toxicity. Cortisone acetate, although exhibit 4 mg/kg resulted, in a majority of the experiments, in a ing no apparent host toxicity, significantly inhibited significant suppression of tumor growth, as compared tumor growth in one experiment out of four. with the effect of 6-AN alone. No effect was observed at TABLE 2 EFFECT OFCOMBININGO-AMINONICOTINAMIDEANDVARIOUSESTROGENICANDNONESTROGENICSUBSTANCES ON THE GROWTHOF ADENOCARCINOMA755 Level of cent estrogen wt.(gm.tumor weight (mg/kg)1410141014101010Exp.no.123123t12345Group6-AN S.E.)2.41± change-3+4+3+2+ oil6-AN+ ses. 0.272.34± stilbestrol6-AN+ 0.243.01± oil6-AN+ ses. 0.281.84± stilbestrol6-AN+ 0.25*3.26± oil6-AN+ ses. 0.41*1.50± 19+ stilbestrol6-AN+ 0.252.41± 10+3-1+6+2+2+5+ oil6-AN+ ses. 0.271.65± hexestrol6-AN+ 0.222.12± dienestrol6-AN+ 0.313.01± oil6-AN+ ses. 0.281.99± hexestrol6-AN+ 0.25*2.26± dienestrol6-AN+ 0.233.26± oil6-AN+ ses. 0.411.46± 19+ + hexestrol ±0.24* 12 6-ANdienestrol6-AN+ 0.34*2.411.63± 9/210/173/181/182/191/207/190/181/200/200/200/201/20Per+13-3+1+3+4+ oil6-AN+ ses. 0.272.27± -17/36-AN+ estradici 0.333.01± oil6-AN+ ses. 0.282.43± estradiol-17/36-AN+ 0.243.26± oil6-AN-f ses. 0.41*1.00± 19+10+11+9-4-4+7+4 estradiol-17/36-AN+ 0.231.18± oil6-AN+ ses. 0.181.22± estradiol-17a6-AN+ 0.111.43± progesterone6-AN+ 0.140.74± cortisone6-AN+ 0.121.30± oil6-AN-f ses. 0.181.49± + phloretinAv. ±0.21Mortality0/170/171/183/191/202/200/171/182/181/182/193/181/203/20 6-Aminonicotinamide dissolved in saline was administered at a level of 2 mg/kg. The hormonal derivatives, given at a level of 10 mg/kg, were dissolved in sesame oil with the exception of cortisone acetate, which was suspended in saline. Therapy was begun 14 days after transplantation and con tinued for six consecutive injections. * Experiments exhibited "t" value of 2.6 or higher. Downloaded from cancerres.aacrjournals.org on September 25, 2021. © 1964 American Association for Cancer Research. DIETRICH—6-Aminonicotinamide Antagonism of Tumor Growth 63 TABLE 3 administered none of the estrogenic substances by them SUMMARYOF BIOLOGICALSTUDIES CONCERNINGTHE EFFECT OF selves demonstrated either tumor or host toxicity (Table STEROIDDERIVATIVESONCARCINOSTASISINTHE PRESENCEOF 1). However, when the estrogenically active derivatives 6-AMINONICOTINAMIDE were combined with nontoxic levels of 6-AN, increased No. EXP. HAVING "I" VALUES host and tumor toxicity was observed. The host toxicity OF 2.6 OR HIGHER was particularly noticeable in the case of diethylstil COMPOUNDStilbestrolDienestrolHexestrolEstradiol-17/3PhloretinProgesteroneCortisoneEstradiol-17aTOTALEXP.10 bestrol and hexestrol. In these studies, however, there was no consistency between host toxicity and inhibition mg/kg6/113/53/53/50/30/41/40/44mg/kg4/60/33/30/31mg/kg0/60/30/30/3of tumor growth—i.e., marked host toxicity was observed in experiments showing no tumor toxicity, and significant antagonism of tumor growth occurred in experiments showing little host toxicity. Thus, it is doubtful whether host toxicity per se played a significant role in retarding tumor growth in these cases. The action of cortisone in these studies is not under stood. When cortisone was used, significant antagonism of tumor growth was observed in one experiment out of mi —m* nil —treatment with 6-AN. four in the case of hormone therapy alone (Table 1) and "¡2=treatment with Estrogen + one experiment out of four in the presence of hormone and + 6-AN. 6-AN (Table 3). The other compounds tested were The results are considered consistent beyond chance variation when "/" is 2.6 or higher. Adenocarcinoma 755 was grown in totally inactive in the absence of 6-AN. C57BL mice. Therapy was begun on well established tumors Whether the effect of these compounds on neoplastic (14-21 days after transplantation). The compounds were given growth is a direct or indirect action of the estrogenic at the dosage indicated for 6 consecutive days. activity of these substances is not known. However, the TOIand mi refer to mean tumor weights of groups of at least extremely high levels of estrogen necessary to elicit a seventeen animals. response and the lack of knowledge whether the activity observed is directly or indirectly of estrogenic nature this level of dienestrol. Increasing the level of hexestrol should not distract from the fact that this experimental to 10 mg/kg resulted in no apparent increase in toxicity. neoplasm appears to exhibit hormonal sensitivity. Fur In the case of dienestrol, however, increasing the level thermore, this suggestive hormone sensitivity is appar administered to 10 mg/kg resulted, in the majority of ently in some manner linked to pyridine nucleotide experiments, in a significant inhibition of tumor growth metabolism, since, in the case of diethylstilbestrol, this as compared with that from 6-AN by itself.
Load more

Recommended publications
  • Therapeutic Class Brand Name P a Status Generic
    P A Therapeutic Class Brand Name Status Generic Name Strength Form Absorbable Sulfonamides AZULFIDINE SULFASALAZINE 250MG/5ML ORAL SUSP Absorbable Sulfonamides AZULFIDINE SULFASALAZINE 500MG TABLET Absorbable Sulfonamides AZULFIDINE SULFASALAZINE 500MG TABLET DR Absorbable Sulfonamides BACTRIM DS SULFAMETHOXAZOLE/TRIMETHO 800-160MG TABLET Absorbable Sulfonamides GANTRISIN SULFISOXAZOLE 500MG TABLET Absorbable Sulfonamides GANTRISIN SULFISOXAZOLE ACETYL 500MG/5ML ORAL SUSP Absorbable Sulfonamides GANTRISIN SULFISOXAZOLE ACETYL 500MG/5ML SYRUP Absorbable Sulfonamides SEPTRA SULFAMETHOXAZOLE/TRIMETHO 200-40MG/5 ORAL SUSP Absorbable Sulfonamides SEPTRA SULFAMETHOXAZOLE/TRIMETHO 400-80MG TABLET Absorbable Sulfonamides SULFADIAZINE SULFADIAZINE 500MG TABLET ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 10-20MG CAPSULE ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 2.5-10MG CAPSULE ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 5-10MG CAPSULE ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 5-20MG CAPSULE P A Therapeutic Class Brand Name Status Generic Name Strength Form ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 5-40MG CAPSULE ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 10-40MG CAPSULE Acne Agents, Systemic ACCUTANE ISOTRETINOIN 10MG CAPSULE Acne Agents, Systemic ACCUTANE ISOTRETINOIN 20MG CAPSULE Acne Agents, Systemic ACCUTANE
    [Show full text]
  • Postmenopausal Pharmacotherapy Newsletter
    POSTMENOPAUSAL PHARMACOTHERAPY September, 1999 As Canada's baby boomers age, more and more women will face the option of Hormone Replacement Therapy (HRT). The HIGHLIGHTS decision can be a difficult one given the conflicting pros and cons. M This RxFiles examines the role and use of HRT, as well as newer Long term HRT carries several major benefits but also risks SERMS and bisphosphonates in post-menopausal (PM) patients. which should be evaluated on an individual and ongoing basis MContinuous ERT is appropriate for women without a uterus HRT MWomen with a uterus should receive progestagen (at least 12 HRT is indicated for the treatment of PM symptoms such as days per month or continuous low-dose) as part of their HRT vasomotor disturbances and urogenital atrophy, and is considered MLow-dose ERT (CEE 0.3mg) + Ca++ appears to prevent PMO primary therapy for prevention and treatment of postmenopausal MBisphosphinates (e.g. alendronate, etidronate) and raloxifene are osteoporosis (PMO).1 Contraindications are reviewed in Table 2. alternatives to HRT in treating and preventing PMO Although HRT is contraindicated in women with active breast or M"Natural" HRT regimens can be compounded but data is lacking uterine cancer, note that a prior or positive family history of these does not necessarily preclude women from receiving HRT.1 Comparative Safety: Because of differences between products, some side effects may be alleviated by switching from one product Estrogen Replacement Therapy (ERT) 2 to another, particularly from equine to plant sources or from oral to Naturally secreted estrogens include: topical (see Table 3 - Side Effects & Their Management).
    [Show full text]
  • The Reactivity of Human and Equine Estrogen Quinones Towards Purine Nucleosides
    S S symmetry Article The Reactivity of Human and Equine Estrogen Quinones towards Purine Nucleosides Zsolt Benedek †, Peter Girnt † and Julianna Olah * Department of Inorganic and Analytical Chemistry, Budapest University of Technology and Economics, Szent Gellért tér 4, H-1111 Budapest, Hungary; [email protected] (Z.B.); [email protected] (P.G.) * Correspondence: [email protected] † These authors contributed equally to this work. Abstract: Conjugated estrogen medicines, which are produced from the urine of pregnant mares for the purpose of menopausal hormone replacement therapy (HRT), contain the sulfate conjugates of estrone, equilin, and equilenin in varying proportions. The latter three steroid sex hormones are highly similar in molecular structure as they only differ in the degree of unsaturation of the sterane ring “B”: the cyclohexene ring in estrone (which is naturally present in both humans and horses) is replaced by more symmetrical cyclohexadiene and benzene rings in the horse-specific (“equine”) hormones equilin and equilenin, respectively. Though the structure of ring “B” has only moderate influence on the estrogenic activity desired in HRT, it might still significantly affect the reactivity in potential carcinogenic pathways. In the present theoretical study, we focus on the interaction of estrogen orthoquinones, formed upon metabolic oxidation of estrogens in breast cells with purine nucleosides. This multistep process results in a purine base loss in the DNA chain (depurination) and the formation of a “depurinating adduct” from the quinone and the base. The point mutations induced in this manner are suggested to manifest in breast cancer development in the long run.
    [Show full text]
  • Steroid Sex Hormones Non Steroid Hormones Fig. A1. Chemical
    Electronic Supplementary Material (ESI) for Analytical Methods. This journal is © The Royal Society of Chemistry 2015 Steroid sex hormones O OH H H H H H H O Testosterone (T) HO Estrone (E1) OH O H H H H H H O HO 17β-Estradiol (17β-E2) 4-Androstene-3,17-dione (AND) OH OH H OH H H H H H H O HO Nandrolone (NAN) Estriol (E3) OH OH H H H H H H O 17α-Methyltestosterone (17α-MT) HO Ethinylestradiol (EE2) OH O O H HO OH H H H H H H O Prednisolone (PRED) O Progesterone (P) Non steroid hormones HO CH3 HO CH3 H C OH H C OH 3 Diethylstilbestrol (DES) 3 Hexestrol (HEX) Fig. A1. Chemical structure of selected endocrine disruptors. Fig. A2. Scheme of SPE procedure: a) PTFE disks, b) nylon filter membrane. Table A1. Characterization data for mesoporous silicas a Material BET surface Pore volume Pore L0C18 Particle morphology Average particle size 2 -1 3 -1 -1 (m g ) (cm g ) diameter (Å) (mmol C18 g ) (length x wide) SBA-15-C18 796 0.88 76 0.69 Cylindrical 1.4 µm x 750 nm a Amount of octadecyl groups per gram of silica Q3 Q4 Q2 DH 50 0 -50 -100 -150 -200 (ppm) 29 Fig. A3. Si NMR spectrum of SBA-15-C18. 140 0 % Weight Loss T 120 -5 100 s s o L Exothermic Procces 80 t -10 ) h C º g i 60 ( e T W Endothermic Procces -15 % 40 20 -20 0 -25 -20 100 200 300 400 500 600 700 800 T (ºC) Fig.
    [Show full text]
  • Structure and Origin of Uterine and Extragenital L=Ibroids Induced
    Structure and Origin of Uterine and Extragenital l=ibroids Induced Experimentally in the Guinea Pig by Prolonged Administration of Estrogens* Alexander Lipschotz, M.D., and Louis Vargas, Jr., M.D. (From Department o/ Experimental Medicine, National Health Service o/the Republic o/Chile, Santiago, Chile) (Received for publication December 13, x94o) The purpose of this communication is to present the These experimentally induced abdominal tumors findings of a detailed microscopical study of the sites present a smooth surface formed of a capsule com- of origin and stages of development of the subserous posed of flattened superficial cells (Plate 2, Figs. 2-A fibroid tumors induced in guinea pigs by prolonged and 2-B). The cells beneath the capsule resemble administration of estrogens. Details of treatment of fibroblasts. These cells have definite boundaries or the animals are given in the explanations of Plates I- 5. they are separated from each other by collagenous Subserous uterine tumors which can be induced in fibers (Plate 4, Fig. ix-C). guinea pigs by prolonged administration of estrogens, The masses of fibroid tumors arising from the apex as described by Nelson (26, 27), were found to be of the uterine horn may enclose the tubes or large fibroids. Lipschiitz, Iglesias, and Vargas (i3, 18, 22) tubal cysts. The demarcation between the muscular have shown that extragenital tumors in the abdominal coat of the tube and the tumor is not always sharp. cavity, induced by estrogens, also were fibroids. The In some instances, especially when the apical fibroid localization of these tumo~:s at various sites on the is small, the tumor is in close contact with an abun- uterus, pancreas, kidney, spleen, etc., have been de- dance of smooth muscle and adipose tissue (Plate 2, scribed by Iglesias (5), Vargas and Lipschiitz (32), Fig.
    [Show full text]
  • Estrogen-Induced Endogenous DNA Adduction
    Proc. Natl. Acad. Sci. USA Vol. 83, pp. 5301-5305, July 1986 Medical Sciences Estrogen-induced endogenous DNA adduction: Possible mechanism of hormonal cancer (estradiol/synthetic estrogens/renal carcinoma/Syrian hamster/32P-labeling analysis) J. G. LIEHR*, T. A. AVITTSt, E. RANDERATHt, AND K. RANDERATHtt *Department of Pharmacology, University of Texas Medical Branch, Galveston, TX 77550; and tDepartment of Pharmacology, Baylor College of Medicine, Houston, TX 77030 Communicated by Paul C. Zamecnik, March 24, 1986 ABSTRACT In animals and humans, estrogens are able to but the mechanism of this effect has not been elucidated. In induce cancer in susceptible target organs, but the mecha- view ofthe extensive use ofcompounds with estrogenic activity nism(s) of estrogen-induced carcinogenesis has not been eluci- in human medicine (20, 21) and in agriculture (22) and the dated. A well-known animal model is the development of renal occurrence of estrogenic compounds as contaminants in food carcinoma in estrogen-treated Syrian hamsters. Previous work (22, 23), it is important to define how these compounds cause demonstrated the presence of covalent DNA addition products cancer. (adducts) in premalignant kidneys of hamsters exposed to the A central question to be addressed in this context is whether synthetic estrogen, diethylstilbestrol, a known human carcin- or not estrogens, like the majority of chemical carcinogens, ogen. In the present study, the natural hormone, 178-estradiol, induce covalent DNA alterations in the target tissue of and several synthetic steroid and stilbene estrogens were exam- carcinogenesis in vivo. In the present study, experiments were ined by a 32P-postlabeling assay for their capacity to cause carried out to search for adduct formation in an established covalent DNA alterations in hamster kidney.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Hormone Replacement Therapy and Osteoporosis
    This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied. AHRQ is the lead Federal agency charged with supporting research designed to improve the quality of health care, reduce its cost, address patient safety and medical errors, and broaden access to essential services. AHRQ sponsors and conducts research that provides evidence-based information on health care outcomes; quality; and cost, use, and access. The information helps health care decisionmakers— patients and clinicians, health system leaders, and policymakers—make more informed decisions and improve the quality of health care services. Systematic Evidence Review Number 12 Hormone Replacement Therapy and Osteoporosis Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 2101 East Jefferson Street Rockville, MD 20852 http://www.ahrq.gov Contract No. 290-97-0018 Task Order No. 2 Technical Support of the U.S. Preventive Services Task Force Prepared by: Oregon Health Sciences University Evidence-based Practice Center, Portland, Oregon Heidi D. Nelson, MD, MPH August 2002 Preface The Agency for Healthcare Research and Quality (AHRQ) sponsors the development of Systematic Evidence Reviews (SERs) through its Evidence-based Practice Program. With guidance from the third U.S. Preventive Services Task Force∗ (USPSTF) and input from Federal partners and primary care specialty societies, two Evidence-based Practice Centers—one at the Oregon Health Sciences University and the other at Research Triangle Institute-University of North Carolina—systematically review the evidence of the effectiveness of a wide range of clinical preventive services, including screening, counseling, immunizations, and chemoprevention, in the primary care setting.
    [Show full text]
  • Studies on Squamous Metaplasia in Rat Bladder II . Effects of Estradiol and Estradiol Plus Hexestrol*T
    Studies on Squamous Metaplasia in Rat Bladder II . Effects of Estradiol and Estradiol plus Hexestrol*t A. ANGRIST, P. CAPURRO, AND B. MOUMGIS (Department of Pathology, Albert Einstein College of Medicine of Yeshiva University, New York 61, N.Y.) SUMMARY The effects of estrogens were studied with and without foreign body (rough glass beads and paraffin pellets) on the metaplasia of the bladder of rats on stock main tenance diet and on a vitamin A-deficient diet. Estradiol increased the degree of metaplasia in the bladder of rats when combined with vitamin A deficiency and/or foreign body stimulation. Estradiol affected bladder epithelium already made squamous more effectively than it did the normal transitional uroepithelium. A high dose of hexestrol, when added to estradiol, showed no enhance ment of the degree of metaplasi.a by estradiol benzoate in the bladder of the rat. The combination of vitamin A deficiency, foreign body in situ, and estrogenadminis tration was an effective means of obtaining keratinizing squamous metaplasia in the urinary bladder for studies of its developmental and reversal changes. In a previous presentation (4) the relation of The animals were divided into the following different forms of foreign-body irritation and of groups (the number of rats surviving with tissue vitamin A deficiency to squamous metaplasia in for study and the total number in each group mi the bladders of rats was reported. It is also known tinily are given following each group): that estrogens will cause squamous metaplasia. I. Stock diet + estradiol (6 survivals/lI rats) The metaplasia following estrogen administration II.
    [Show full text]
  • Use of Estrogen-Dihydropyridine Compounds For
    Europaisches Patentamt J European Patent Office © Publication number: 0 220 844 Office europeen des brevets A2 EUROPEAN PATENT APPLICATION © Application number: 86307536.2 © int. ci.<: A61K 31/57 A61 K , 31/565 , A61K 31/44 © Date of filing: 01.10.86 The title of the invention has been amended © Applicant: UNIVERSITY OF FLORIDA (Guidelines for Examination in the EPO, A-lll, 207 Tigert Hall 7.3). Gainesville Florida 32611 (US) @ Inventor: Bodor, Nicholas S. ® Priority: 22.10.85 US 790159 7211 Southwest 97th Lane Gainesville Florida 32608(US) © Date of publication of application: Inventor: Estes, Kerry S. 06.05.87 Bulletin 87/19 5604 Southwest 83rd Drive Gainesville Florida 32608(US) © Designated Contracting States: Inventor: Simpkins, James W. AT BE CH DE ES FR GB GR IT LI LU NL SE 1722 Northwest 11th Road Gainesville Florida 32605(US) © Representative: Pendlebury, Anthony et al Page, White & Fairer 5 Plough Place New Fetter Lane London EC4A 1HY(GB) © Use of estrogen-dihydropyridlne compounds for weight control. © The invention provides the use of a compound of the formula [E-DHC] (I) or a non-toxic pharmaceutically acceptable salt thereof, wherein [E] is an estrogen and [DHC] is the reduced, biooxidizable, blood-brain barrier penetrating, lipoidal form of a dihydropyridines*pyridinium salt redox carrier in the preparation of a medicament for controlling mammalian body weight. Novel compositions for weight control comprising a compound of formula (I) or its salt are also disclosed. A preferred compound for use herein is an I estradiol derivative, namely, 1 7/3-[(1 -methyl-1 ,4-dihydro-3-pyridinyl)carbonyloxy]estra-1 ,3,5(1 0)-trien-3-ol.
    [Show full text]
  • Steroidal Estrogens
    FINAL Report on Carcinogens Background Document for Steroidal Estrogens December 13 - 14, 2000 Meeting of the NTP Board of Scientific Counselors Report on Carcinogens Subcommittee Prepared for the: U.S. Department of Health and Human Services Public Health Service National Toxicology Program Research Triangle Park, NC 27709 Prepared by: Technology Planning and Management Corporation Canterbury Hall, Suite 310 4815 Emperor Blvd Durham, NC 27703 Contract Number N01-ES-85421 Dec. 2000 RoC Background Document for Steroidal Estrogens Do not quote or cite Criteria for Listing Agents, Substances or Mixtures in the Report on Carcinogens U.S. Department of Health and Human Services National Toxicology Program Known to be Human Carcinogens: There is sufficient evidence of carcinogenicity from studies in humans, which indicates a causal relationship between exposure to the agent, substance or mixture and human cancer. Reasonably Anticipated to be Human Carcinogens: There is limited evidence of carcinogenicity from studies in humans which indicates that causal interpretation is credible but that alternative explanations such as chance, bias or confounding factors could not adequately be excluded; or There is sufficient evidence of carcinogenicity from studies in experimental animals which indicates there is an increased incidence of malignant and/or a combination of malignant and benign tumors: (1) in multiple species, or at multiple tissue sites, or (2) by multiple routes of exposure, or (3) to an unusual degree with regard to incidence, site or type of tumor or age at onset; or There is less than sufficient evidence of carcinogenicity in humans or laboratory animals, however; the agent, substance or mixture belongs to a well defined, structurally-related class of substances whose members are listed in a previous Report on Carcinogens as either a known to be human carcinogen, or reasonably anticipated to be human carcinogen or there is convincing relevant information that the agent acts through mechanisms indicating it would likely cause cancer in humans.
    [Show full text]
  • The Rabbits Are Prepared ..." - the Development of Ethinylestradiol and Ethinyltestosterone Frobenius W J
    Journal für Reproduktionsmedizin und Endokrinologie – Journal of Reproductive Medicine and Endocrinology – Andrologie • Embryologie & Biologie • Endokrinologie • Ethik & Recht • Genetik Gynäkologie • Kontrazeption • Psychosomatik • Reproduktionsmedizin • Urologie "The Rabbits are Prepared ..." - The Development of Ethinylestradiol and Ethinyltestosterone Frobenius W J. Reproduktionsmed. Endokrinol 2011; 8 (Sonderheft 1), 32-57 www.kup.at/repromedizin Online-Datenbank mit Autoren- und Stichwortsuche Offizielles Organ: AGRBM, BRZ, DVR, DGA, DGGEF, DGRM, D·I·R, EFA, OEGRM, SRBM/DGE Indexed in EMBASE/Excerpta Medica/Scopus Krause & Pachernegg GmbH, Verlag für Medizin und Wirtschaft, A-3003 Gablitz FERRING-Symposium digitaler DVR 2021 Mission possible – personalisierte Medizin in der Reproduktionsmedizin Was kann die personalisierte Kinderwunschbehandlung in der Praxis leisten? Freuen Sie sich auf eine spannende Diskussion auf Basis aktueller Studiendaten. SAVE THE DATE 02.10.2021 Programm 12.30 – 13.20Uhr Chair: Prof. Dr. med. univ. Georg Griesinger, M.Sc. 12:30 Begrüßung Prof. Dr. med. univ. Georg Griesinger, M.Sc. & Dr. Thomas Leiers 12:35 Sind Sie bereit für die nächste Generation rFSH? Im Gespräch Prof. Dr. med. univ. Georg Griesinger, Dr. med. David S. Sauer, Dr. med. Annette Bachmann 13:05 Die smarte Erfolgsformel: Value Based Healthcare Bianca Koens 13:15 Verleihung Frederik Paulsen Preis 2021 Wir freuen uns auf Sie! Development of Ethinylestradiol and Ethinyltestosterone “The Rabbits are Prepared …” – The Development of Ethinylestradiol and Ethinyltestosterone W. Frobenius In an exciting scientific neck-and-neck race, European and American scientists in the late 1920s and early 1930s isolated the ovarian, placental, and testicular hormones. At the same time the constitution of the human sex steroids was elucidated. However, it soon emerged that with oral administration the therapeutic value of the natural substances was extremely limited.
    [Show full text]